Outcomes of tacrolimus therapy in adults with refractory membranous nephrotic syndrome: A prospective, multicenter clinical trial

American Journal of the Medical Sciences

Volumn 345, Issue 2, 2013, Pages 81-87

  Chen, Wei ^a   Liu, Qinghua ^a   Liao, Yunhua ^b   Yang, Zhenhua ^b   Chen, Jian ^c   Fu, Junzhou ^d   Zhang, Jinli ^e   Kong, Yaozhong ^f   Fu, Ping ^g   Lou, Tanqi ^a   Liu, Zhengrong ^a   Ji, Yulian ^a   Li, Zhibin ^h,i   Yu, Xueqing ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b GUANGXI MEDICAL UNIVERSITY   (China)

^c FUZHOU GENERAL HOSPITAL   (China)

^d GUANGZHOU FIRST PEOPLE'S HOSPITAL   (China)

^e People's Hospital of Yunnan Province   (China)

^f Department of Nephrology   (China)

^g SICHUAN UNIVERSITY   (China)

^h SOUTHERN MEDICAL UNIVERSITY   (China)

ⁱ First Affiliated Hospital   (China)

Author keywords

Membranous nephropathy; Nephrotic syndrome; Refractory; Tacrolimus

Indexed keywords

CHOLESTEROL; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; LOW DENSITY LIPOPROTEIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; SERUM ALBUMIN; TACROLIMUS; TRIACYLGLYCEROL;

ADULT; ADULT DISEASE; ALBUMIN BLOOD LEVEL; ARTICLE; CHINESE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CORTICOSTEROID THERAPY; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HAND TREMOR; HUMAN; HYPERGLYCEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; LIPOPROTEIN BLOOD LEVEL; MALE; MULTICENTER STUDY; NEPHROTIC SYNDROME; NEPHROTOXICITY; PROTEINURIA; RELAPSE; REMISSION; TRIACYLGLYCEROL BLOOD LEVEL; UPPER RESPIRATORY TRACT INFECTION;

EID: 84873167464     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e31824ce676     Document Type: Article

References (42)

1. Cattran DC. Idiopathic membranous glomerulonephritis. Kidney Int 2001;59:1983-94
2. du Buf- Vereijken PW, Branten AJ, Wetzels JF. Idiopathic membranous nephropathy: Outline and rationale of a treatment strategy. Am J Kidney Dis 2005;46:1012-29
3. Schieppati A, Mosconi L, Perna A, et al. Prognosis of untreated patients with idiopathic membranous nephropathy. N Engl J Med 1993;329:85-9
4. Troyanov S, Wall CA, Miller JA, et al; Toronto Glomerulonephritis Registry Group. Idiopathic membranous nephropathy: Definition and relevance of a partial remission. Kidney Int 2004;66:1199-205
5. Ponticelli C, Zucchelli P, Passerini P, et al. A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. Kidney Int 1995;48:1600-4
6. du Buf-Vereijken PW, Branten AJ, Wetzels JF; Membranous Nephropathy Study Group. Cytotoxic therapy for membranous nephropathy and renal insufficiency: Improved renal survival but high relapse rate. Nephrol Dial Transplant 2004;19:1142-8
7. Torres A, Domínguez-Gil B, Carreño A, et al. Conservative versus immunosuppressive treatment of patients with idiopathic membranous nephropathy. Kidney Int 2002;61:219-27
8. Jha V, Ganguli A, Saha TK, et al. A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy. J Am Soc Nephrol 2007;18:1899-904
9. Cattran DC. Evidence-based recommendations for the management of glomerulonephritis. Introduction. Kidney Int Suppl 1999;70:S1-2
10. Artz MA, Boots JM, Ligtenberg G, et al. Conversion from cyclosporine to tacrolimus improves quality-of-life indices, renal graft function and cardiovascular risk profile. Am J Transplant 2004;4:937-45
11. Jurewicz WA. Tacrolimus versus cyclosporin immunosuppression: Long-term outcome in renal transplantation. Nephrol Dial Transplant 2003;18(suppl 1):i7-11
12. Praga M, Barrio V, Juárez GF, et al. Grupo Español de Estudio de la Nefropatía Membranosa. Tacrolimus monotherapy in membranous nephropathy: A randomized controlled trial. Kidney Int 2007;71:924-30
13. Chen W, Tang X, Liu Q, et al. Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: A multicenter randomized clinical trial. Am J Kidney Dis 2011;57:235-44
14. Ponticelli C, Altieri P, Scolari F, et al. A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. J Am Soc Nephrol 1998;9:444-50
15. Ma YC, Zuo L, Chen JH, et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol 2006;17:2937-44
16. Ponticelli C, Rizzoni G, Edefonti A, et al. A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome. Kidney Int 1993;43:1377-84
17. Vercauteren SB, Bosmans JL, Elseviers MM, et al. A meta-analysis and morphological review of cyclosporine-induced nephrotoxicity in auto-immune diseases. Kidney Int 1998;54:536-45
18. Polanco N, Gutiérrez E, Covarsí A, et al Grupo de Estudio de las Enfermedades Glomerulares de la Sociedad Española de Nefrología. Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J Am Soc Nephrol 2010;21:697-704
19. Passerini P, Pasquali S, Cesana B, et al. Long-term outcome of patients with membranous nephropathy after complete remission of proteinuria. Nephrol Dial Transplant 1989;4:525-9
20. Arikan H, Koc M, Cakalagaoglu F, et al. Tacrolimus rescue therapy in resistant or relapsing cases of primary glomerulonephritis. J Nephrol 2008;21:713-21
21. Chen M, Li H, Li XY, et al; Chinese Nephropathy Membranous Study Group. Tacrolimus combined with corticosteroids in treatment of nephrotic idiopathic membranous nephropathy: A multicenter randomized controlled trial. Am J Med Sci 2010;339:233-8
22. Li X, Li H, Ye H, et al. Tacrolimus therapy in adults with steroid- and cyclophosphamide-resistant nephrotic syndrome and normal or mildly reduced GFR. Am J Kidney Dis 2009;54:51-8
23. Ning YM, Sánchez ER. Potentiation of glucocorticoid receptor-mediated gene expression by the immunophilin ligands FK506 and rapamycin. J Biol Chem 1993;268:6073-6
24. Davies TH, Ning YM, Sánchez ER. Differential control of glucocorticoid receptor hormone-binding function by tetratricopeptide repeat (TPR) proteins and the immunosuppressive ligand FK506. Biochemistry 2005;44:2030-8
25. Textor SC, Wiesner R, Wilson DJ, et al. Systemic and renal hemodynamic differences between FK506 and cyclosporine in liver transplant recipients. Transplantation 1993;55:1332-9
26. Textor SC, Burnett JC Jr, Romero JC, et al. Urinary endothelin and renal vasoconstriction with cyclosporine or FK506 after liver transplantation. Kidney Int 1995;47:1426-33
27. Faul C, Donnelly M, Merscher-Gomez S, et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med 2008;14:931-8
28. Winn MP. 2007 Young Investigator Award: TRP'ing into a new era for glomerular disease. J Am Soc Nephrol 2008;19:1071-5
29. Wang Y, Jarad G, Tripathi P, et al. Activation of NFAT signaling in podocytes causes glomerulosclerosis. J Am Soc Nephrol 2010;21: 1657-66
30. Philibert D, Cattran D. Remission of proteinuria in primary glomerulonephritis: We know the goal but do we know the price? Nat Clin Pract Nephrol 2008;4:550-9
31. Gulati S, Prasad N, Sharma RK, et al. Tacrolimus: A new therapy for steroid-resistant nephrotic syndrome in children. Nephrol Dial Transplant 2008;23:910-3
32. Loeffler K, Gowrishankar M, Yiu V. Tacrolimus therapy in pediatric patients with treatment-resistant nephrotic syndrome. Pediatr Nephrol (Berlin, Germany) 2004;19:281-7
33. McCauley J, Shapiro R, Ellis D, et al. Pilot trial of FK 506 in the management of steroid-resistant nephrotic syndrome. Nephrol Dial Transplant 1993;8:1286-90
34. McCauley J, Tzakis AG, Fung JJ, et al. FK 506 in steroid-resistant focal sclerosing glomerulonephritis of childhood. Lancet 1990;335: 674
35. Pennesi M, Gagliardo A, Minisini S. Effective tacrolimus treatment in a child suffering from severe nephrotic syndrome. Pediatr Nephrol (Berlin, Germany) 2003;18:477-8
36. Schweda F, Liebl R, Riegger GA, et al. Tacrolimus treatment for steroid- and cyclosporin-resistant minimal-change nephrotic syndrome. Nephrol Dial Transplant 1997;12:2433-5
37. Segarra A, Vila J, Pou L, et al. Combined therapy of tacrolimus and corticosteroids in cyclosporin-resistant or -dependent idiopathic focal glomerulosclerosis: A preliminary uncontrolled study with prospective follow-up. Nephrol Dial Transplant 2002;17:655-62
38. Choudhry S, Bagga A, Hari P, et al. Efficacy and safety of tacrolimus versus cyclosporine in children with steroid-resistant nephrotic syndrome: A randomized controlled trial. Am J Kidney Dis 2009;53: 760-9
39. Cattran DC, Alexopoulos E, Heering P, et al. Cyclosporin in idiopathic glomerular disease associated with the nephrotic syndrome: Workshop recommendations. Kidney Int 2007;72:1429-47
40. Alexopoulos E, Papagianni A, Tsamelashvili M, et al. Induction and long-term treatment with cyclosporine in membranous nephropathy with the nephrotic syndrome. Nephrol Dial Transplant 2006;21: 3127-32
41. Morgan C, Sis B, Pinsk M, et al. Renal interstitial fibrosis in children treated with FK506 for nephrotic syndrome. Nephrol Dial Transplant 2011;26:2860-5
42. Segarra A, Praga M, Ramos N, et al. Successful treatment of membranous glomerulonephritis with rituximab in calcineurin inhibitordependent patients. Clin J Am Soc Nephrol 2009;4:1083-8.